

Analysis and use of a statutory dataset in the elimination of hepatitis C across 15 NHS Trusts

HEP C U Later

Fair R¹, Heaps C¹, Hansford L¹, Hughes L¹, Burch D¹, Lincoln C¹, Mullaney T¹.

¹Hep C U Later (Inclusion part of Midlands Partnership University NHS Foundation Trust - MPFT)


Background:

The NHS Addiction Providers Alliance (NHSAPA) is a group of 18 NHS Trusts in the UK providing addiction services. In 2020, 15 Trusts signed up to Hep C U Later (HCUL), which is the NHSAPA's HCV elimination project, representing over **30,000** patients, with an estimated 36% at risk of contracting hepatitis C (HCV).


The data analytic component provides high-level statistical analysis, using subsets of standardised Statutory National Drug Treatment datasets (NDTMS). This is provided monthly to HCUL under data sharing agreements using unique client identifiers. In 2022, the use of data was enhanced to enable analysis and subsequent targeting for testing and treatment of HCV. The analysis identified individual patients requiring interventions and the initiation of HCV treatment packages. In 2023, the performance management was further developed with the introduction of the UK's Drug Treatment Providers 4 micro-elimination targets.

Methodology:

By providing analysis of NDTMS data:



Monthly dashboards are created, along with specific data spreadsheets, which are then returned to services.



These enable targeted testing on a needs basis, and an assessment of progress towards micro-elimination.



We ensure all those identified as RNA+ are referred and supported into treatment and SVRs are obtained.



Robust monitoring for reinfections is also being completed using the data.

Effectiveness:

Using data-driven testing, the project has seen:




42,000+
people *tested*
for HCV



2,393+
successfully
treated for HCV



significant improvements
in HCV data *quality*



The data analysis has allowed
20 services
to declare and maintain *micro-elimination* of HCV (based on 4 micro-elimination criteria).

Conclusion and next steps:



The program has been successful in moving the NHSAPA towards the World Health Organization (WHO) elimination target by using advanced data analytics and AI to enable the services to manage and maintain micro-elimination.

Disclosure of interest statement:

This project has been supported through an Association of the British Pharmaceutical Industry (ABPI) 'Joint Working' initiative between Gilead Sciences Ltd., and Midlands Partnership University NHS Foundation Trust.